Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score
-
Branko Srećković
,
Ivan Soldatovic
Abstract
Background:
Abdominal adiposity has a central role in developing insulin resistance (IR) by releasing pro-inflammatory cytokines. Patients with metabolic syndrome (MS) have higher values of homocysteine. Hyperhomocysteinemia correlates with IR, increasing the oxidative stress. Oxidative stress causes endothelial dysfunction, hypertension and atherosclerosis. The objective of the study was to examine the correlation of homocysteine with siMS score and siMS risk score and with other MS co-founding factors.
Methods:
The study included 69 obese individuals (age over 30, body mass index [BMI] >25 kg/m2), classified into two groups: I-with MS (33 patients); II-without MS (36 patients). Measurements included: anthropometric parameters, lipids, glucose regulation parameters and inflammation parameters. IR was determined by homeostatic model assessment for insulin resistance (HOMA-IR). ATP III classification was applied for diagnosing MS. SiMS score was used as continuous measure of metabolic syndrome.
Results:
A significant difference between groups was found for C-reactive protein (CRP) (p<0.01) apolipoprotein (Apo) B, HOMA-IR and acidum uricum (p<0.05). siMS risk score showed a positive correlation with homocysteine (p=0.023), while siMS score correlated positively with fibrinogen (p=0.013), CRP and acidum uricum (p=0.000) and homocysteine (p=0.08). Homocysteine correlated positively with ApoB (p=0.036), HbA1c (p=0.047), HOMA-IR (p=0.008) and negatively with ApoE (p=0.042).
Conclusions:
Correlation of siMS score with homocysteine, fibrinogen, CRP and acidum uricum indicates that they are co-founding factors of MS. siMS risk score correlation with homocysteine indicates that hyperhomocysteinemia increases with age. Hyperhomocysteinemia is linked with genetic factors and family nutritional scheme, increasing the risk for atherosclerosis.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7–9.10.1161/01.CIR.93.1.7Search in Google Scholar
2. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol 2004;93:439–53.10.1007/s00392-004-0075-3Search in Google Scholar
3. Guilland JC, Favier A, Potier de Courcy G, Galan P, Hercberg S. Hyperhomocysteinaemia: an independent risk factor or a simple marker of vascular disease? 2. Epidemiological data. Pathol Biol (Paris) 2003;51:111–21.10.1016/S0369-8114(03)00105-6Search in Google Scholar
4. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002;288:2015–22.10.1001/jama.288.16.2015Search in Google Scholar PubMed
5. Ray JG. Meta-analysis of hyperhomocysteinaemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158:2101–6.10.1001/archinte.158.19.2101Search in Google Scholar PubMed
6. Foncea R, Carvajal C, Almarza C, Leighton F. Endothelial cell oxidative stress and signal transduction. Biol Res 2000;33:89–96.10.4067/S0716-97602000000200008Search in Google Scholar PubMed
7. Sengwayo D, Moraba M, Motaung S. Association of homocysteinaemia with hyperglycaemia, dyslipidaemia, hypertension and obesity. Cardiovasc J Afr 2013;24:265–9.10.5830/CVJA-2013-059Search in Google Scholar PubMed PubMed Central
8. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, et al. Hyperhomocysteinaemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001;107:675–83.10.1172/JCI10588Search in Google Scholar PubMed PubMed Central
9. Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis 1997;20: 307–15.10.1023/A:1005377310872Search in Google Scholar
10. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457–61.10.1126/science.1103160Search in Google Scholar PubMed
11. Hajer GR, van der Graaf Y, Olijhoek JK, Verhaar MC, Visseren FL, Group SS. Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. Heart 2007;93:216–20.10.1136/hrt.2006.093971Search in Google Scholar PubMed PubMed Central
12. Srećković B. Determination of homocysteine level as an independent risk factor for coronary heart disease. Subspecialty thesis, University of Belgrade, School of Medicine, 2010.Search in Google Scholar
13. Soldatovic I, Vukovic R, Culafic D, Gajic M, Dimitrijevic-Sreckovic V. siMS Score: Simple Method for Quantifying Metabolic Syndrome. PLoS One 2016;11:e0146143.10.1371/journal.pone.0146143Search in Google Scholar PubMed PubMed Central
14. Sertoglu E, Kayadibi H, Uyanik M. Biochemical view on “Homocysteine and metabolic syndrome: from clustering to additional utility in prediction of coronary heart disease”. J Cardiol 2015;65:439.10.1016/j.jjcc.2014.11.010Search in Google Scholar PubMed
15. Dimitrijevic-Sreckovic V, Soldatovic I, Culafic D, Sreckovic B, Popovic S, Djordjevic P, et al. Liver function test changes in centrally obese youth with metabolic syndrome in a Serbian population. Metab Syndr Relat Disord 2013;11:427–33.10.1089/met.2012.0154Search in Google Scholar PubMed
16. Sreckovic B, Sreckovic VD, Soldatovic I, Colak E, Sumarac-Dumanovic M, Janeski H, et al. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes Metab Syndr 2017;11:179–82.10.1016/j.dsx.2016.08.026Search in Google Scholar PubMed
17. Atif A, Rizvi MA, Tauheed S, Aamir I, Majeed F, Siddiqui K, et al. Serum homocysteine concentrations in patients with hypertension. Pak J Physiol 2008;4:21–2.Search in Google Scholar
18. Dimitrijević-Srećković V, Colak E, Djordjević P, Gostiljac D, Srećković B, Popovic S, et al. Prothrombogenic factors and reduced antioxidative deffence in the cildren and adolescents with pre-methaboloc and metabolic syndrome. Clin Chem Lab Med 2007;45:1140–4.10.1515/CCLM.2007.259Search in Google Scholar PubMed
19. Molnár D, Decsi T, Koletzko B. Reduced antioxidant status in obese children with multimetabolic syndrome. Int J Obes Relat Metab Disord 2004;28:1197–202.10.1038/sj.ijo.0802719Search in Google Scholar PubMed
20. Scorsatto M, Uehara SK, Luiz RR, de Oliveira GM, Rosa G. Fortification of flours with folic acid reduces homocysteine levels in Brazilian women. Nutr Res 2011;31:889–95.10.1016/j.nutres.2011.10.003Search in Google Scholar PubMed
21. Faeh D, Chiolero A, Paccaud F. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about? Swiss Med Wkly 2006;136:7455–6.Search in Google Scholar
22. Kazemi MB, Eshraghian K, Omrani GR, Lankarani KB, Hosseini E. Homocysteine level and coronary artery disease. Angiology 2006;57:9–14.10.1177/000331970605700102Search in Google Scholar PubMed
23. Rocha E. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. Rev Port Cardiol 2000;19:1319–20.Search in Google Scholar
24. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995;274:1049–57.10.1001/jama.274.13.1049Search in Google Scholar
©2018 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Editorial
- New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics
- Original Articles
- Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies
- Correlation between plasma concentrations of tramadol and its metabolites and the incidence of seizure in tramadol-intoxicated patients
- Effect of the African-specific promoter polymorphisms on the SLC22A2 gene expression levels
- Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)
- Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score
- Case Report
- Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
Articles in the same Issue
- Frontmatter
- Editorial
- New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics
- Original Articles
- Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies
- Correlation between plasma concentrations of tramadol and its metabolites and the incidence of seizure in tramadol-intoxicated patients
- Effect of the African-specific promoter polymorphisms on the SLC22A2 gene expression levels
- Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia)
- Homocysteine is the confounding factor of metabolic syndrome-confirmed by siMS score
- Case Report
- Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
